Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

BTIG ups Vericel PT to $30 from $23

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $30 from $23 after an analyst and investor event focused primarily on NexoBrid, a recently licensed burn enzymatic debridement product from MediWound. ...

October 19, 2020

Markets

Maxim starts Plus Therapeutics at buy; PT $6

Maxim Group launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $6. The stock closed at $2.56 on Oct. 15. The company’s lead asset, rhenium nanoliposome (RNL), is being developed...

October 16, 2020

Markets

BTIG starts Aldeyra Therapeutics at buy; PT $29

BTIG initiated coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and $29 price target. The stock closed at $6.86 on Oct. 15. Aldeyra is targeting reactive aldehyde species (RASP) for a range of...

October 16, 2020

Markets

AGP starts InspireMD at buy; PT 70 cents

Alliance Global Partners initiated coverage of InspireMD (NYSE American:NSPR) with a “buy” rating and price target of 70 cents. The stock closed at 32 cent on Oct. 15. InspireMD has developed the CGuard EPS (Embolic...

October 16, 2020

Developments

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Anavex Life Sciences (NASDAQ:AVXL) reported positive results from its Phase 2 study evaluating ANAVEX2-73 for the treatment of Parkinson’s disease dementia. The proof-of-concept study enrolled 132 patients who received...

October 15, 2020

Developments

Titan Pharma to focus on ProNeura-based product development

Titan Pharmaceuticals (NASDAQ:TTNP) reported that it will discontinue U.S. Probuphine sales and wind down commercialization activities as it restructures to focus on ProNeura-based product development. “Marketing of...

October 15, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-102 for the treatment of Rett syndrome. Rett syndrome is a genetic neurodevelopmental disorder characterized by...

October 14, 2020

Executive Moves

Long-time biotech analyst Doug Loe joins Leede Jones Gable

Doug Loe, Ph.D. has joined Leede Jones Gable as it continues to grow its capital markets team, boosting healthcare and biotechnology, and building on recent additions in sales and trading. Dr. Loe, who brings more than...

October 14, 2020

Markets

Ladenburg starts Cogent Biosciences at buy; PT $4

Ladenburg Thalmann launched coverage of Cogent Biosciences (NASDAQ:COGT) with a “buy” rating and $4 price target. The stock closed at $2.89 on Oct. 13. Cogent has a late-stage clinical asset, CGT9486, in development for...

October 14, 2020

Markets

HCW starts Humanigen at buy; PT $31

H.C. Wainwright launched coverage of Humanigen (NASDAQ:HGEN) with a “buy” rating and price target of $31. The stock closed at $12.03 on Oct. 13. The company’s lead asset, lenzilumab, is an antibody targeting...

October 14, 2020

Developments

Evelo doses first patient in Phase 2 psoriasis study

Evelo Biosciences (NASDAQ:EVLO) dosed the first patient in its Phase 2 study evaluating EDP1815 for the treatment of mild-to-moderate psoriasis. The placebo-controlled study will enroll 225 patients to evaluate three...

October 13, 2020

Developments

AnaptysBio reports positive topline data from Phase 2 pustular psoriasis trial

AnaptysBio (NASDAQ:ANAB) reported positive topline data from an interim analysis of its Phase 2 trial evaluating imsidolimab or the treatment of generalized pustular psoriasis (GPP). GPP is a rare, chronic, life...

October 13, 2020

Subscribe